Africa could be on the brink of a historic breakthrough in the battle against HIV/AIDS, following the emergence of Lenacapavir, a long-acting injectable drug hailed as a potential game-changer in HIV prevention.
The treatment, developed by Gilead Sciences, offers a six-month protection window with a single injection, a remarkable leap from the daily oral regimens that have long posed adherence challenges across the continent.
In groundbreaking trials conducted in sub-Saharan Africa among cisgender women, Lenacapavir demonstrated unprecedented results, with zero new HIV infections reported in participants who received the injection. According to the World Health Organization (WHO), the drug showed a 96 percent reduction in HIV incidence compared to background infection rates and proved 89 percent more effective than the standard daily pill regimen.
The WHO has since welcomed the U.S. Food and Drug Administration’s approval of Lenacapavir for HIV prevention, describing it as “a major step forward in achieving global HIV elimination targets.”
Africa’s role in the Lenacapavir rollout has been central. Gilead has entered into royalty-free licensing agreements with six generic manufacturers to ensure access in 120 high-incidence, resource-limited countries, most of them in sub-Saharan Africa. Egyptian-based EVA Pharma is among the licensed producers, marking a significant milestone in local manufacturing and self-reliance.
In Nigeria, early access agreements have already slashed the potential cost from nearly P396 040.40 ($28,000) to about P565.77 ($40) per person per year for low- and middle-income countries. South Africa, one of the hardest-hit nations, has announced plans to introduce the injection in more than 300 public clinics by April 2026, focusing on districts with the highest HIV prevalence.
The simplicity of the twice-yearly injection could help overcome some of the most persistent barriers to HIV prevention in Africa including daily pill fatigue, transport costs, and the stigma associated with being seen taking medication.
“Lenacapavir has the potential to reshape HIV prevention entirely,” said a WHO spokesperson. “By reducing the need for frequent clinic visits, it allows health systems to reach the most vulnerable populations — young women, key populations, and people in remote areas.”
The innovation arrives at a crucial time, as African nations continue striving toward the UNAIDS goal of ending HIV as a public health threat by 2030. With over 25 million people living with HIV in sub-Saharan Africa, the stakes are immense. Public health experts warn, however, that the success of Lenacapavir will depend on strong local frameworks. Countries will need to accelerate regulatory approvals, expand cold-chain storage capacity, and secure sustainable funding to ensure equitable access. The WHO also emphasizes that prevention must go hand in hand with education, stigma reduction, and testing to maintain the human-centered approach that underpins effective HIV control.
Despite these challenges, optimism remains high. Trials in Uganda have shown low resistance levels, with less than two percent of participants carrying any known mutations against Lenacapavir. The drug’s unique mechanism targeting the viral capsid, the protein shell that protects HIV’s genetic material gives it an edge over existing treatments, making resistance less likely and protection longer lasting.
With cost reductions and technology transfer agreements, Africa could become both a production hub and a global model for equitable access.
Currently, Gilead Sciences is in the process of testing a Lenacapvir injection that is aimed towards being taken once a year, with early results showing a 95% efficacy rate.
